(MENAFN- PR Newswire) DUBLIN, May 9, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH ) will participate in a Fireside Chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ Monday, May 20 at 11:30 AM EDT (8:30 AM PDT / 4:30 PM IST) and will be hosting in-person meetings with the investment community at the conference.
Webcast of the event may be accessed by visiting Theravance , under the Investors section, Events and Presentations. Replay of the webcast will be archived on the Company's website for 30 days.
About Theravance Biopharma
Theravance Biopharma, Inc.'s focus is to deliver Medicines that Make a Difference® in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational once-daily norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in MSA patients. The Company is committed to creating/driving shareholder value.
For more information, please visit .
THERAVANCE BIOPHARMA®, THERAVANCE® and the Cross/Star logo are registered trademarks of the
Theravance Biopharma
group of companies (in the
U.S.
and certain other countries).
YUPELRI®
is a registered trademark of
Mylan Specialty L.P., a
Viatris company. Trademarks, trade names or service marks of other companies appearing in this press release are the property of their respective owners.
Contact:
[email protected]
650-808-4045
SOURCE Theravance Biopharma, Inc.
MENAFN09052024003732001241ID1108193016
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.